270 related articles for article (PubMed ID: 25447595)
1. Tranilast: a review of its therapeutic applications.
Darakhshan S; Pour AB
Pharmacol Res; 2015 Jan; 91():15-28. PubMed ID: 25447595
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic potential of tranilast, an anti-allergy drug, in proliferative disorders.
Rogosnitzky M; Danks R; Kardash E
Anticancer Res; 2012 Jul; 32(7):2471-8. PubMed ID: 22753703
[TBL] [Abstract][Full Text] [Related]
3. Tranilast, an antifibrogenic agent, ameliorates a dietary rat model of nonalcoholic steatohepatitis.
Uno M; Kurita S; Misu H; Ando H; Ota T; Matsuzawa-Nagata N; Kita Y; Nabemoto S; Akahori H; Zen Y; Nakanuma Y; Kaneko S; Takamura T
Hepatology; 2008 Jul; 48(1):109-18. PubMed ID: 18571789
[TBL] [Abstract][Full Text] [Related]
4. Tranilast, an anti-allergic drug, down-regulates the growth of cultured neurofibroma cells derived from neurofibromatosis type 1.
Yamamoto M; Yamauchi T; Okano K; Takahashi M; Watabe S; Yamamoto Y
Tohoku J Exp Med; 2009 Mar; 217(3):193-201. PubMed ID: 19282654
[TBL] [Abstract][Full Text] [Related]
5. Anti-cancer effects of Tranilast: An update.
Osman S; Raza A; Al-Zaidan L; Inchakalody VP; Merhi M; Prabhu KS; Abdelaziz N; Hydrose S; Uddin S; Dermime S
Biomed Pharmacother; 2021 Sep; 141():111844. PubMed ID: 34174504
[TBL] [Abstract][Full Text] [Related]
6. N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) inhibits transforming growth factor-beta relesase and reduces migration and invasiveness of human malignant glioma cells.
Platten M; Wild-Bode C; Wick W; Leitlein J; Dichgans J; Weller M
Int J Cancer; 2001 Jul; 93(1):53-61. PubMed ID: 11391621
[TBL] [Abstract][Full Text] [Related]
7. Tranilast inhibits the cell growth of normal human keratinocytes in vitro.
Kubo M; Zhao Y; Moriguchi T
Arch Dermatol Res; 2012 Nov; 304(9):745-53. PubMed ID: 23053220
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of interferon-gamma and interleukin-2 production from lymphocytes stimulated with food antigens by an anti-allergic drug, Tranilast, in patients with food-sensitive atopic dermatitis.
Kondo N; Fukutomi O; Shinbara M; Orii T
Biotherapy; 1994; 8(1):19-22. PubMed ID: 7547077
[TBL] [Abstract][Full Text] [Related]
9. Tranilast Inhibits Genes Functionally Involved in Cell Proliferation, Fibrosis, and Epigenetic Regulation and Epigenetically Induces miR-29c Expression in Leiomyoma Cells.
Chuang TD; Khorram O
Reprod Sci; 2017 Sep; 24(9):1253-1263. PubMed ID: 28114878
[TBL] [Abstract][Full Text] [Related]
10. Effect of tranilast on matrix metalloproteinase-1 secretion from human gingival fibroblasts in vitro.
Maita E; Sato M; Yamaki K
J Periodontol; 2004 Aug; 75(8):1054-60. PubMed ID: 15455731
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Effects of Long-Term Administration of Tranilast in an Animal Model for the Treatment of Fibroids.
Chuang TD; Munoz L; Quintanilla D; Boos D; Khorram O
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445642
[TBL] [Abstract][Full Text] [Related]
12. Tranilast attenuates vascular hypertrophy, matrix accumulation and growth factor overexpression in experimental diabetes.
Bonnet F; Cao Z; Cooper ME; Cox AJ; Kelly DJ; Gilbert RE
Diabetes Metab; 2003 Sep; 29(4 Pt 1):386-92. PubMed ID: 14526266
[TBL] [Abstract][Full Text] [Related]
13. The Effect of Tranilast 8% Liposomal Gel Versus Placebo on Post-Cesarean Surgical Scars: A Prospective Double-Blind Split-Scar Study.
Kohavi L; Sprecher E; Zur E; Artzi O
Dermatol Surg; 2017 Sep; 43(9):1157-1163. PubMed ID: 28825957
[TBL] [Abstract][Full Text] [Related]
14. Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes.
Izumi K; Mizokami A; Li YQ; Narimoto K; Sugimoto K; Kadono Y; Kitagawa Y; Konaka H; Koh E; Keller ET; Namiki M
Prostate; 2009 Aug; 69(11):1222-34. PubMed ID: 19434660
[TBL] [Abstract][Full Text] [Related]
15. Suppression of matrix metalloproteinase production in nasal fibroblasts by tranilast, an antiallergic agent, in vitro.
Shimizu T; Kanai K; Asano K; Hisamitsu T; Suzaki H
Mediators Inflamm; 2005 Aug; 2005(3):150-9. PubMed ID: 16106101
[TBL] [Abstract][Full Text] [Related]
16. Tranilast inhibits protein kinase C-dependent signalling pathway linked to angiogenic activities and gene expression of retinal microcapillary endothelial cells.
Koyama S; Takagi H; Otani A; Suzuma K; Nishimura K; Honda Y
Br J Pharmacol; 1999 May; 127(2):537-45. PubMed ID: 10385256
[TBL] [Abstract][Full Text] [Related]
17. Suppression of atherosclerotic development in Watanabe heritable hyperlipidemic rabbits treated with an oral antiallergic drug, tranilast.
Matsumura T; Kugiyama K; Sugiyama S; Ota Y; Doi H; Ogata N; Oka H; Yasue H
Circulation; 1999 Feb; 99(7):919-24. PubMed ID: 10027816
[TBL] [Abstract][Full Text] [Related]
18. Anti-platelet action of an anti-allergic agent, N-(3',4'-dimethoxycinnamoyl)anthranilic acid (tranilast).
Iwasa Y; Iwasa T; Matsui K; Yoshimura T; Tanaka N; Miyazaki K
Eur J Pharmacol; 1986 Jan; 120(2):231-4. PubMed ID: 2419148
[TBL] [Abstract][Full Text] [Related]
19. [The effect of tranilast on subepithelial corneal opacity after excimer laser keratectomy].
Sakai T; Okamoto S; Iwaki Y
Nippon Ganka Gakkai Zasshi; 1997 Oct; 101(10):783-7. PubMed ID: 9369059
[TBL] [Abstract][Full Text] [Related]
20. Tranilast ameliorates renal tubular damage in unilateral ureteral obstruction.
Miyajima A; Asano T; Asano T; Yoshimura I; Seta K; Hayakawa M
J Urol; 2001 May; 165(5):1714-8. PubMed ID: 11342962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
